The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2148-2160

  Nam, Hyun Jin ^a   Kim, Hwang Phill ^a   Yoon, Young Kwang ^a   Song, Sang Hyun ^a   Min, Ah Rum ^a   Han, Sae Won ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Oh, Do Youn ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Biliary tract cancer cell lines; Gemcitabine; Irreversible pan HER inhibitor; PF00299804

Indexed keywords

AFATINIB; CANERTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; LAPATINIB; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILIARY TRACT CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MAGEH1 GENE; PRIORITY JOURNAL; PROTEIN FAMILY; RRM1 GENE; TS GENE;

ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINONES; RECEPTORS, GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84875512435     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9782-6     Document Type: Article

References (61)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368-1378
2. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, Mossner J, Caca K (2006) Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 17:783-795
3. Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa I, Roa JC, Thomas MB (2007) HER Receptor family: novel candidate for targeted therapy for gallbladder and extrahe-patic bile duct cancer. Gastrointest Cancer Res 1:221-227
4. Tonini G, Frato ME, Vincenzi B, Santini D (2010) Chemotherapy in biliary tract cancer. Eur Rev Med Pharmacol Sci 14:371-374
5. Tonini G, Virzi V, Fratto ME, Vincenzi B, Santini D (2009) Targeted therapy in biliary tract cancer: 2009 update. Future Oncol 5:1675-1684
6. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG (2009) EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15:4511-4517
7. Herberger B, Berger W, Puhalla H, Schmid K, Novak S, Brandstetter A, Pirker C, Gruenberger T, Filipits M (2009) Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapa-mycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther 8:1547-1556
8. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangio-carcinoma. Br J Cancer 98:418-425
9. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, Imaoka S, Tsujimoto M, Higashiyama S, Monden M, Matsuura N (2001) Expression and clinical significance of the erbB family in intra-hepatic cholangiocellular carcinoma. Pathol Res Pract 197:95-100
10. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206:356-365
11. Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131:649-652
12. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, Venesio T, Capussotti L, Risio M, Aglietta M (2006) Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12:1680-1685
13. Pawson T (2004) Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116:191-203
14. Mass RD (2004) The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58:932-940
15. Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32S-40S
16. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F (2010) Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 10:631
17. Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Rogler G (2010) Expression of growth factor receptors and targeting of EGFR in cholangiocarci-noma cell lines. BMC Cancer 10:302
18. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, Shibata T (2009) Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 100:1257-1266
19. Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S (2006) Assessment of gefitinib-and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. Mol Cancer Ther 5:1895-1903
20. Ariyama H, Qin B, Baba E, Tanaka R, Mitsugi K, Harada M, Nakano S (2006) Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 97:724-734
21. Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J (2005) Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res 11:5572-5580
22. Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bour-aoud N, Kulesza P, Sebastiani V, Maitra A, Hidalgo M (2005) Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65:3003-3010
23. Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS (2010) Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie 33:45-47
24. Tada M, Nakai Y, Sasaki T, Hamada T, Nagano R, Mohri D, Miyabayashi K, Yamamoto K, Kogure H, Kawakubo K, Ito Y, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Isayama H, Omata M, Koike K (2011) Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World J Clin Oncol 2:158-163
25. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD (2010) Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28:3491-3497
26. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069-3074
27. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR (2009) A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64:777-783
28. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Janne PA (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932
29. Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, Fry DW, Zhu T, Loi CM, Fakhoury SA, Schlosser KM, Sexton KE, Winters RT, Reed JE, Bridges AJ, Lettiere DJ, Baker DA, Yang J, Lee HT, Tecle H, Vincent PW (2008) Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7:1880-1889
30. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Janne PA (2010) Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29:2346-2356
31. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Janne PA (2010) Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77-88
32. Ku JL, Park JG (2005) Biology of SNU cell lines. Cancer Res Treat 37:1-19
33. Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, Kim SW, Park YH, Hwang JH, Yoon YB, Park JG (2002) Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer 87:187-193
34. Nam HJ, Kim HP, Yoon YK, Hur HS, Song SH, Kim MS, Lee GS, Han SW, Im SA, Kim TY, Oh DY, Bang YJ (2011) Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett 302:155-165
35. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
36. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH (2001) The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10- hydroxycamptothecin and top-otecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61:739-748
37. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501
38. Lee KW, Kim JH, Park JH, Kim HP, Song SH, Kim SG, Kim TY, Jong HS, Jung KH, Im SA, Kim NK, Bang YJ (2006) Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 26:3429-3438
39. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocar-cinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
40. Yoon YK, Kim HP, Han SW, Hur HS, Test YOh (2009) article sample title placed here. Mol Cancer Ther 8:2526-2536
41. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69:3256-3261
42. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17
43. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22
44. Kadota M, SatoM, DuncanB, OoshimaA, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T, Tsukada K, Dunn BK, Wakefield LM, Lee MP (2009) Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res 69:7357-7365
45. Yoon YK, Kim HP, Han SW, Test YOh (2010) article sample title placed here. Mol Carcinog 49:353-362
46. Nabeya Y, Suzuki T, Furuya A, Koide N, Ohkoshi M, Takiguchi M, Ochiai T, Matsubara H, Hiwasa T (2011) Calpain regulates thymidylate synthase-5-fluoro- dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. Cancer Sci 102:1509-1515
47. Komori S, Osada S, Mori R, Matsui S, Sanada Y, Tomita H, Tokuyama Y, Takahashi T, Yamaguchi K, Yoshida K (2010) Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer. Pancreas 39:1284-1292
48. Shi Y, Chen L, Li J, Lu YL, Jiao SC (2010) Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and beta-tubulin3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 32:375-382
49. Ferrandina G, Mey V, Nannizzi S, Ricciardi S, Petrillo M, Ferlini C, Danesi R, Scambia G, Del Tacca M (2010) Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol 65:679-686
50. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M (2010) Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12:807-817
51. Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M (2008) Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcita-bine in pancreatic cancer. Anticancer Res 28:2205-2212
52. Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T (2010) Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci 101:882-888
53. Weigt J, Malfertheiner P (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Expert Rev Gastroenterol Hepatol 4:395-397
54. Wiedmann MW, Mossner J (2010) Molecular targeted therapy of biliary tract cancer-results of the first clinical studies. Curr Drug Targets 11:834-850
55. Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, Gutman N, Kennedy T (2008) Lapatinib/gemcitabine and lapatinib/gemcitabine/oxalipla-tin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol 31:140-144
56. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16:5489-5498
57. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY, Bang YJ (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett
58. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY (2009) Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate syn-thase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 4:e5933
59. Li XD, Geng YT, Wu CP, Shen H, Sun J, Shu YQ, Yin YM (2010) Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie 33:466-469
60. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosen-sitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355
61. Osawa K (2009) Gene polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 12:837-840